Pfizer Betting Big on Cancer Research in $11.4 Billion Acquisition of Array BioPharma

Pfizer is delving deeper into cancer research with a roughly $11.4 billion deal for Array BioPharma, a drug developer that has seen its shares soar since announcing positive clinical trial results earlier this spring. Pfizer said Monday it will pay $48 per share in cash for Array, whose product portfolio includes a treatment combination used […]

Data Sheet–Drug Discovery Shifting From Treatment to Cure

Some takeaways from the final day of Fortune’s Brainstorm Health conference in San Diego: * Freda Lewis-Hall, chief patient officer of Pfizer, lamented the sorry state of keeping patients informed about the state of the art in medical technology. “I can know what the Kardashians ate for breakfast this morning,” she said. “But I can’t […]